JPWO2021247604A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021247604A5 JPWO2021247604A5 JP2022573633A JP2022573633A JPWO2021247604A5 JP WO2021247604 A5 JPWO2021247604 A5 JP WO2021247604A5 JP 2022573633 A JP2022573633 A JP 2022573633A JP 2022573633 A JP2022573633 A JP 2022573633A JP WO2021247604 A5 JPWO2021247604 A5 JP WO2021247604A5
- Authority
- JP
- Japan
- Prior art keywords
- tgf
- receptor
- pharmaceutical composition
- binding domain
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 69
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 69
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 65
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 65
- 229920001184 polypeptide Polymers 0.000 claims description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 239000003795 chemical substances by application Substances 0.000 claims description 45
- 102000003675 cytokine receptors Human genes 0.000 claims description 45
- 108010057085 cytokine receptors Proteins 0.000 claims description 45
- 210000004027 cell Anatomy 0.000 claims description 41
- 230000004913 activation Effects 0.000 claims description 39
- 239000012190 activator Substances 0.000 claims description 31
- 108010000499 Thromboplastin Proteins 0.000 claims description 28
- 102000002262 Thromboplastin Human genes 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 18
- 102400000401 Latency-associated peptide Human genes 0.000 claims description 16
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 16
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 239000000556 agonist Substances 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 8
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 201000008968 osteosarcoma Diseases 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 claims description 4
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 claims description 4
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 claims description 4
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 claims description 4
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 claims description 4
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 claims description 4
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 claims description 4
- 102100036407 Thioredoxin Human genes 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 206010002329 Aneurysm Diseases 0.000 claims description 3
- 102000014461 Ataxins Human genes 0.000 claims description 3
- 108010078286 Ataxins Proteins 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 208000012526 B-cell neoplasm Diseases 0.000 claims description 3
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 206010065687 Bone loss Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims description 3
- 206010024604 Lipoatrophy Diseases 0.000 claims description 3
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 206010060872 Transplant failure Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000018180 degenerative disc disease Diseases 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 claims description 3
- 208000006132 lipodystrophy Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 230000008085 renal dysfunction Effects 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000001076 sarcopenia Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- 229940124753 IL-2 agonist Drugs 0.000 claims description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 201
- 102000003812 Interleukin-15 Human genes 0.000 description 17
- 108090000172 Interleukin-15 Proteins 0.000 description 17
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 108010002335 Interleukin-9 Proteins 0.000 description 4
- 108010074108 interleukin-21 Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 3
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 101150044980 Akap1 gene Proteins 0.000 description 2
- 108010016529 Bacillus amyloliquefaciens ribonuclease Proteins 0.000 description 2
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2
- 108010005730 R-SNARE Proteins Proteins 0.000 description 2
- 102000000583 SNARE Proteins Human genes 0.000 description 2
- 108010041948 SNARE Proteins Proteins 0.000 description 2
- 102000002215 Synaptobrevin Human genes 0.000 description 2
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 2
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 2
- 102000050389 Syntaxin Human genes 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000010094 cellular senescence Effects 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 102000056003 human IL15 Human genes 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 102000003137 synaptotagmin Human genes 0.000 description 2
- 108060008004 synaptotagmin Proteins 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032933P | 2020-06-01 | 2020-06-01 | |
| US63/032,933 | 2020-06-01 | ||
| USPCT/US2020/035598 | 2020-06-01 | ||
| PCT/US2020/035598 WO2021247003A1 (en) | 2020-06-01 | 2020-06-01 | Methods of treating aging-related disorders |
| US202063118536P | 2020-11-25 | 2020-11-25 | |
| US63/118,536 | 2020-11-25 | ||
| PCT/US2021/035285 WO2021247604A1 (en) | 2020-06-01 | 2021-06-01 | Methods of treating aging-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023527869A JP2023527869A (ja) | 2023-06-30 |
| JP2023527869A5 JP2023527869A5 (https=) | 2024-06-12 |
| JPWO2021247604A5 true JPWO2021247604A5 (https=) | 2024-06-12 |
Family
ID=76523519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573633A Pending JP2023527869A (ja) | 2020-06-01 | 2021-06-01 | 加齢関連障害の治療法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4157460A1 (https=) |
| JP (1) | JP2023527869A (https=) |
| KR (1) | KR20230031280A (https=) |
| AU (1) | AU2021283199B2 (https=) |
| CA (1) | CA3184756A1 (https=) |
| IL (1) | IL298608A (https=) |
| WO (1) | WO2021247604A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023019215A1 (en) * | 2021-08-11 | 2023-02-16 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases |
| JP2025508939A (ja) * | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| CN116199787A (zh) * | 2022-08-02 | 2023-06-02 | 四川大学华西医院 | 一种基于uPA的GFD结构域构建的嵌合抗原受体免疫细胞制备及其应用 |
| WO2024211893A2 (en) * | 2023-04-07 | 2024-10-10 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| KR20260003467A (ko) * | 2024-06-28 | 2026-01-07 | (주)네이처글루텍 | 항산화 및 항노화 펩타이드를 포함하는 조성물 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US6117980A (en) | 1997-02-21 | 2000-09-12 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| JP2001206899A (ja) | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| ES2353273T3 (es) | 2000-12-26 | 2011-02-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticuerpos anti-cd28. |
| WO2003104425A2 (en) | 2002-06-07 | 2003-12-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Novel stable anti-cd22 antibodies |
| JP4463104B2 (ja) | 2002-08-30 | 2010-05-12 | 財団法人化学及血清療法研究所 | ヒト抗ヒトインターロイキン−６抗体及び該抗体フラグメント |
| EP1400534B1 (en) | 2002-09-10 | 2015-10-28 | Affimed GmbH | Human CD3-specific antibody with immunosuppressive properties |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| KR20060015482A (ko) | 2003-03-21 | 2006-02-17 | 와이어쓰 | 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료 |
| US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| ES2375481T3 (es) | 2004-03-30 | 2012-03-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos. |
| CA2763671A1 (en) | 2005-04-26 | 2006-11-02 | Pfizer Inc. | P-cadherin antibodies |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| WO2009120922A2 (en) | 2008-03-27 | 2009-10-01 | Zymogenetics, Inc. | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
| LT3216803T (lt) | 2008-06-25 | 2020-06-10 | Novartis Ag | Stabilūs ir tirpūs antikūnai, slopinantys vegf |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| US9273136B2 (en) | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011100538A1 (en) | 2010-02-11 | 2011-08-18 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-cd200 antibodies |
| WO2011127324A2 (en) | 2010-04-08 | 2011-10-13 | JN Biosciences, LLC | Antibodies to cd122 |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP2012034668A (ja) | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| CN105884900A (zh) | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| SMT201800269T1 (it) | 2011-04-25 | 2018-07-17 | Daiichi Sankyo Co Ltd | Anticorpo anti-b7-h3 |
| SG10201603962TA (en) | 2011-05-25 | 2016-07-28 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory disorders |
| US8753640B2 (en) | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
| WO2012170470A1 (en) | 2011-06-06 | 2012-12-13 | Board Of Regents Of The University Of Nebraska | Compositions and methods for detection and treatment of cancer |
| CN103747803B (zh) | 2011-06-22 | 2016-10-12 | 国家医疗保健研究所 | 抗axl抗体及其用途 |
| AU2012335205A1 (en) | 2011-11-11 | 2014-05-29 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
| KR101535341B1 (ko) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| CA2876285A1 (en) | 2012-08-08 | 2014-02-13 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
| US20150218280A1 (en) | 2012-08-10 | 2015-08-06 | University Of Southern California | CD20 scFv-ELPs METHODS AND THERAPEUTICS |
| WO2014033130A1 (en) | 2012-08-28 | 2014-03-06 | Institut Curie | Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection |
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| WO2014095808A1 (en) | 2012-12-17 | 2014-06-26 | Delenex Therapeutics Ag | Antibodies against il-1 beta |
| TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| WO2014159531A1 (en) | 2013-03-14 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases |
| AU2014268364A1 (en) | 2013-05-24 | 2015-12-10 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| KR102127408B1 (ko) | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| FR3021970B1 (fr) | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
| AU2015305754B2 (en) | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| JP7211703B2 (ja) | 2014-12-22 | 2023-01-24 | ザ ロックフェラー ユニバーシティー | 抗ｍｅｒｔｋアゴニスト抗体及びその使用 |
| US10744157B2 (en) | 2015-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using |
| KR20170138494A (ko) | 2015-04-17 | 2017-12-15 | 엘살리스 비오떼끄 | 항-ｔｙｒ０３ 항체 및 이의 용도 |
| KR20240025721A (ko) * | 2015-06-15 | 2024-02-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 노화와 연관된 질환을 치료하기 위한 방법 및 조성물 |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| CA2994858C (en) | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| CN108367071B (zh) | 2015-11-13 | 2022-05-13 | 达纳-法伯癌症研究所有限公司 | 用于癌症免疫疗法的nkg2d-ig融合蛋白 |
| MX2018010445A (es) | 2016-03-01 | 2019-10-17 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
| WO2017189526A1 (en) | 2016-04-25 | 2017-11-02 | Musc Foundation For Research Development | Activated cd26-high immune cells and cd26-negative immune cells and uses thereof |
| MX2019007981A (es) * | 2017-01-03 | 2019-10-15 | Bioatla Llc | Terapeutica de proteinas para el tratamiento de celulas senescentes. |
| GB201708456D0 (en) * | 2017-05-26 | 2017-07-12 | Medical Res Council | Senolytic compounds |
| EP3676289B1 (en) * | 2017-08-28 | 2026-03-04 | Altor BioScience, LLC | Il-15-based fusions to il-7 and il-21 |
| IL312612A (en) * | 2018-07-11 | 2024-07-01 | Rubedo Life Sciences Inc | Senolytic compositions and uses thereof |
| US11401324B2 (en) * | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| US11518792B2 (en) * | 2018-08-30 | 2022-12-06 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CA3109361A1 (en) * | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
-
2021
- 2021-06-01 JP JP2022573633A patent/JP2023527869A/ja active Pending
- 2021-06-01 IL IL298608A patent/IL298608A/en unknown
- 2021-06-01 CA CA3184756A patent/CA3184756A1/en active Pending
- 2021-06-01 KR KR1020237000057A patent/KR20230031280A/ko active Pending
- 2021-06-01 EP EP21733685.8A patent/EP4157460A1/en active Pending
- 2021-06-01 WO PCT/US2021/035285 patent/WO2021247604A1/en not_active Ceased
- 2021-06-01 AU AU2021283199A patent/AU2021283199B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6906653B2 (ja) | 三重特異性結合タンパク質と使用方法 | |
| US11872271B2 (en) | High-affinity anti-VEGF antibody KLHa505 | |
| JP6457431B2 (ja) | 抗アクチビンａ抗体およびその使用 | |
| TW509697B (en) | Humanized antibody against parathyroid hormone related peptide | |
| TW201920263A (zh) | 檢查點抑制劑雙特異性抗體 | |
| JP2012507299A (ja) | Ｌｉｇｈｔ標的分子およびその使用 | |
| JP2018516969A (ja) | Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 | |
| KR101800467B1 (ko) | 루푸스 치료 방법 및 조성물 | |
| CN114269782B (zh) | 抗tigit抗体及其应用 | |
| JP7809324B2 (ja) | ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療 | |
| JP7362614B2 (ja) | 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質 | |
| KR20200088883A (ko) | 표적치료법을 위한 체크포인트 억제력을 갖는 이중작용성 단백질 | |
| TW201609805A (zh) | 結合ｅｇｆｒ及ｍｅｔ之多功能抗體 | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| WO2022117572A2 (en) | An ltbr agonist in combination therapy against cancer | |
| JP2022512905A (ja) | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 | |
| US20240010731A1 (en) | Combination product for the treatment of cancer | |
| JP2021518132A (ja) | Ｇｉｐｒ抗体及びｇｌｐ−１とのその融合タンパク質、並びにその医薬組成物及び用途 | |
| JP2023502876A (ja) | がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質 | |
| WO2023236991A1 (zh) | 靶向her2，pd-l1和vegf的三特异性抗体 | |
| JPWO2021247604A5 (https=) | ||
| JP2025540215A (ja) | Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法 | |
| WO2024188222A1 (zh) | 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途 | |
| TW201713346A (zh) | 調控免疫反應之方法及抗體 |